Share Covaxin formula, cap vaccine prices: Delhi govt tells Centre
India | May 14, 2021 15:06 ISTDelhi Health Minister also urged the Centre to share Bharat Biotech's Covaxin formula with other companies to prevent a shortage.
Delhi Health Minister also urged the Centre to share Bharat Biotech's Covaxin formula with other companies to prevent a shortage.
The IIT Alumni Council-founded Megalab has secured a Rs 300-crore seed funding and is developing a two-dose Ayurveda-based coronavirus vaccin.
A total of 1.47 crore people have been vaccinated against COVID-19 in Gujarat so far. While 1.09 crore people have received the first dose, 37.89 lakh others were administered the second dose.
Biovet Pvt Ltd, an associate firm of Bharat Biotech, is confident of making a plant at Manjari in Pune "fully functional" for vaccine production by August-end.
Gurugram administration will organise a day-long 'drive-in vaccination' programme to administer the second dose of Covishield to the 45+ age group at the DLF City Centre Mall on Friday.
The Hyderabad-based firm is supplying Covaxin to 18 states, including Andhra Pradesh, Haryana, Odisha, Assam, Jammu & Kashmir, Tamil Nadu, Bihar, Jharkhand and Delhi.
The DGCI has approved Bharat Biotech's COVID-19 vaccine Covaxin for phase II/III clinical trial on those aged between two to 18 years. The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur.
Covaxin is currently being administered to the people in the country along with Covishield. Hyderabad-based Bharat Biotech is manufacturing Covaxin.
Due to the shortage of vaccines, the vaccination drive in Mumbai has been badly hit since the last one month.
The Uttar Pradesh government has made arrangements to provide doses free of cost to everyone and assured that the state is receiving enough vaccines with the help of the Centre.
The WHO has said that several religious and political mass gathering events in India led to the rise in Covid-19 transmission.
Serum Institute and Bharat Biotech have submitted to the Centre that they can ramp up production of Covishield and Covaxin to 10 crore and 7.8 crore doses, respectively, by August.
Bharat Biotech co-founder and Joint MD Suchitra Ella tweeted this on Wednesday amid reports of some states voicing their unhappiness over supplies.
BIBCOL will manufacture 2 crore doses of Covaxin every month at its Bulandshahar plant in Uttar Pradesh.
Union Health Minister Harsh Vardhan will chair a meeting with Health Ministers of states to review the vaccination drive.
The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur.
Bharat Biotech on Tuesday said it will continue the steady supply of its COVID-19 vaccine Covaxin, adding the jab has been directly supplied to 18 states since May 1.
The Aam Aadmi Party leader urged the Centre to replenish Covaxin and Covishield stocks and said otherwise "we will have no option but to stop vaccination drive".
Over 2,600 people between 18-44 years got vaccinated for COVID-19 in Gautam Buddh Nagar on Monday, as the inoculation for the age category officially began in the western Uttar Pradesh district.
The minister's remarks came a day after Chief Minister Arvind Kejriwal urged the Centre to direct manufacturers to increase vaccine supplies to the capital between May and July.
Top News
Latest News
